Drug profile · INN
darunavir + cobicistat + emtricitabine + tenofovir alafenamide
SYMTUZA
darunavir + cobicistat + emtricitabine + tenofovir alafenamide (SYMTUZA) is an FDA-listed pharmaceutical active ingredient. Associated with Janssen-Cilag Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — darunavir + cobicistat + emtricitabine + tenofovir alafenamide
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
darunavir + cobicistat + emtricitabine + tenofovir alafenamide (SYMTUZA) is an FDA-listed pharmaceutical active ingredient. Associated with Janssen-Cilag Pty Ltd.
Key facts
INN darunavir + cobicistat + emtricitabine + tenofovir alafenamide
Brand SYMTUZA
Originator Janssen-Cilag Pty Ltd
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is darunavir + cobicistat + emtricitabine + tenofovir alafenamide?
darunavir + cobicistat + emtricitabine + tenofovir alafenamide (SYMTUZA) is an FDA-listed pharmaceutical active ingredient. Associated with Janssen-Cilag Pty Ltd.
What is the brand name for darunavir + cobicistat + emtricitabine + tenofovir alafenamide?
SYMTUZA is a marketed brand name for darunavir + cobicistat + emtricitabine + tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.